Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Stacy L. Moulder"'
Autor:
Peng Wei, Wei T. Yang, Lumarie Santiago, Marion E. Scoggins, Rosalind P. Candelaria, Alastair M. Thompson, Gary J. Whitman, Beatriz E. Adrada, Tanya W. Moseley, Jason B White, Vicente Valero, Stacy L. Moulder, Elizabeth Ravenberg, Jennifer K. Litton, Gaiane M. Rauch
Publikováno v:
Cancer
BACKGROUND Heterogeneity exists in the response of triple-negative breast cancer (TNBC) to standard anthracycline (AC)/taxane-based neoadjuvant systemic therapy (NAST), with 40% to 50% of patients having a pathologic complete response (pCR) to therap
Autor:
Ricardo H. Alvarez, Vicente Valero, Banu Arun, Gabriel N. Hortobagyi, Nuhad K. Ibrahim, Debu Tripathy, Diane Liu, Naoto T. Ueno, Marc Uemura, Wendy Woodward, Bora Lim, Kanwal Pratap Singh Raghav, John Thomas French, Kenneth R. Hess, Bisrat G. Debeb, Stacy L. Moulder
Publikováno v:
Cancer. 124:2299-2305
Background Inflammatory breast cancer (IBC) is associated with a poor prognosis and high risk of central nervous system (CNS) metastases. Methods We retrospectively reviewed stage III-IBC patients compared with noninflammatory invasive ductal carcino
Autor:
Gary J. Whitman, Joe Ensor, Andrew J. Bishop, Michael C. Stauder, Karen E. Hoffman, Mark A. Edson, Gildy Babiera, Sandra Whaley Bishnoi, Stacy L. Moulder, Thomas A. Buchholz, Vicente Valero, Simona F. Shaitelman, Wendy A. Woodward, Naoto T. Ueno
Publikováno v:
Cancer. 121:4324-4332
BACKGROUND This study sought to determine outcomes for patients with metastatic breast cancer (MBC) with no evidence of disease (NED) after treatment and to identify factors predictive of outcomes once the status of NED was attained. METHODS This stu
Autor:
Marc I, Uemura, John T, French, Kenneth R, Hess, Diane, Liu, Kanwal, Raghav, Gabriel N, Hortobagyi, Banu K, Arun, Vicente, Valero, Naoto T, Ueno, Ricardo H, Alvarez, Wendy A, Woodward, Bisrat G, Debeb, Stacy L, Moulder, Bora, Lim, Debu, Tripathy, Nuhad K, Ibrahim
Publikováno v:
Cancer. 124(11)
Inflammatory breast cancer (IBC) is associated with a poor prognosis and high risk of central nervous system (CNS) metastases.We retrospectively reviewed stage III-IBC patients compared with noninflammatory invasive ductal carcinoma (NI-IDC) patients
Autor:
Welela Tereffe, Isabelle Bedrosian, Stacy L. Moulder, Amal Melhem-Bertrand, Abenaa M. Brewster, Tunghi May Pini, Richard L. Theriault, Pragati S. Advani, Shon Black, Jun Ying
Publikováno v:
Cancer. 120:894-900
BACKGROUND Adherence to guidelines for surveillance mammography and clinic visits is an important component of breast cancer survivorship care. Identifying ethnic disparities in adherence may lead to improved care delivery and outcomes. METHODS Recor
Autor:
Sharon H. Giordano, Abeena Brewster, Gabriel N. Hortobagyi, Edgardo Rivera, Hai T. Tran, Ana M. Gonzalez-Angulo, Gregory W. Gladish, Massimo Cristofanilli, Daniel J. Booser, Julia A. Moore, James L. Murray, Stacy L. Moulder, Joe Ensor
Publikováno v:
Cancer. 118:2378-2384
BACKGROUND: Inhibition of mammalian target of rapamycin with everolimus may improve the efficacy of taxanes. Everolimus and docetaxel are both metabolized by CYP3A4, which could result in a pharmacokinetic (PK) interaction. METHODS: Fifteen patients
Autor:
Vicente Valero, Peter F. Thall, Andrew D. Seidman, Kristine Broglio, Susan G. Arbuck, Frankie A. Holmes, Aman U. Buzdar, Anthony W. Tolcher, Gabriel N. Hortobagyi, Stacy L. Moulder
Publikováno v:
Cancer. 116:814-821
Purpose To compare efficacy and toxicity profiles of paclitaxel using 3-hour versus 96-hour infusion schedules.
Autor:
Nickola Valkov, Jimin Choi, Jana L. Gump, Pamela N. Munster, Susan Minton, Anthony Neuger, Daniel M. Sullivan, Richard Lush, Ji-Hyun Lee, Stacy L. Moulder, Mira Lacevic
Publikováno v:
Cancer. 113:2646-2654
BACKGROUND. Gemcitabine incorporation into DNA enhances cleavage complexes in vitro when combined with topoisomerase I inhibitors and demonstrates synergy in cancer cells when given with irinotecan. Topoisomerase I inhibitors require that topoisomera
Autor:
David S, Hong, Ignacio, Garrido-Laguna, Suhendan, Ekmekcioglu, Gerald S, Falchook, Aung, Naing, Jennifer J, Wheler, Siqing, Fu, Stacy L, Moulder, Sarina, Piha-Paul, Apostolia M, Tsimberidou, YueJin, Wen, Kirk S, Culotta, Kenna, Anderes, Darren W, Davis, Wen, Liu, Goldy C, George, Luis H, Camacho, Susan, Percy Ivy, Razelle, Kurzrock
Publikováno v:
Cancer. 120(14)
The current study was conducted to evaluate the safety and biological activity of dual inhibition of the vascular endothelial growth factor (VEGF) pathway with combined bevacizumab and cediranib (a VEGF receptor tyrosine kinase inhibitor).This was a
Autor:
Rashmi K, Murthy, Ankur, Varma, Priyankana, Mishra, Kenneth R, Hess, Elliana, Young, James L, Murray, Kimberly H, Koenig, Stacy L, Moulder, Amal, Melhem-Bertrandt, Sharon H, Giordano, Daniel, Booser, Vicente, Valero, Gabriel N, Hortobagyi, Francisco J, Esteva
Publikováno v:
Cancer. 120(13)
The purpose of the current study was to describe the outcomes of patients with human epidermal growth factor receptor 2 (HER2)-overexpressed/amplified (HER2+) early breast cancer who received adjuvant or neoadjuvant trastuzumab-based therapy and were